Total Payments
$285,525
2024 Payments
$24,444
Companies
49
Transactions
641
Medicare Patients
8,244
Medicare Billing
$865,773
Payment Breakdown by Category
Other$158,415 (55.5%)
Consulting$72,607 (25.4%)
Travel$34,273 (12.0%)
Food & Beverage$19,798 (6.9%)
Education$359.86 (0.1%)
Research$72.50 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $128,400 | 54 | 45.0% |
| Consulting Fee | $72,607 | 30 | 25.4% |
| Travel and Lodging | $34,273 | 59 | 12.0% |
| Honoraria | $27,015 | 17 | 9.5% |
| Food and Beverage | $19,798 | 464 | 6.9% |
| Compensation for serving as faculty or as a speaker for an accredited or certified continuing education program | $3,000 | 1 | 1.1% |
| Education | $359.86 | 6 | 0.1% |
| Unspecified | $72.50 | 10 | 0.0% |
Payments by Type
General
$285,453
631 transactions
Research
$72.50
1 transactions
Ownership
$0
9 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Biotech, Inc. | $115,585 | 178 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $55,409 | 32 | $0 (2023) |
| SN Holdings, LLC | $23,629 | 38 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $14,327 | 28 | $0 (2024) |
| Dendreon Pharmaceuticals LLC | $8,407 | 39 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $7,726 | 14 | $0 (2024) |
| Astellas Pharma US Inc | $7,263 | 53 | $0 (2023) |
| Clovis Oncology, Inc. | $6,897 | 11 | $0 (2019) |
| PFIZER INC. | $5,885 | 30 | $0 (2024) |
| UroGPO LLC | $5,156 | 13 | $0 (2020) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $24,444 | 83 | Janssen Biotech, Inc. ($19,083) |
| 2023 | $28,810 | 66 | SN Holdings, LLC ($9,697) |
| 2022 | $43,066 | 78 | Janssen Biotech, Inc. ($15,173) |
| 2021 | $29,252 | 46 | Janssen Biotech, Inc. ($10,131) |
| 2020 | $7,880 | 21 | TOLMAR Pharmaceuticals, Inc. ($3,900) |
| 2019 | $58,071 | 126 | Janssen Biotech, Inc. ($42,488) |
| 2018 | $64,241 | 149 | Janssen Scientific Affairs, LLC ($37,418) |
| 2017 | $29,761 | 72 | Janssen Scientific Affairs, LLC ($8,286) |
All Payment Transactions
641 individual payment records from CMS Open Payments — Page 1 of 26
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/19/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: ONCOLOGY | ||||||
| 12/18/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $18.32 | General |
| Category: Oncology | ||||||
| 12/16/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $18.27 | General |
| Category: HORMONE THERAPY | ||||||
| 12/14/2024 | AstraZeneca Pharmaceuticals LP | IMFINZI (Biological) | Consulting Fee | Cash or cash equivalent | $1,395.00 | General |
| Category: Oncology | ||||||
| 12/13/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Food and Beverage | In-kind items and services | $18.56 | General |
| Category: Oncology | ||||||
| 11/14/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug) | Food and Beverage | In-kind items and services | $98.67 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $173.00 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/06/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.46 | General |
| Category: ONCOLOGY | ||||||
| 11/01/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $550.00 | General |
| Category: Oncology | ||||||
| 10/31/2024 | Tolmar, Inc. | ELIGARD (Drug), JATENZO | Food and Beverage | Cash or cash equivalent | $16.14 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 10/25/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $19.23 | General |
| Category: HORMONE THERAPY | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $2,180.00 | General |
| 10/24/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 10/24/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $79.71 | General |
| 10/24/2024 | Janssen Biotech, Inc. | — | Food and Beverage | In-kind items and services | $48.87 | General |
| 10/21/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $19.36 | General |
| Category: HORMONE THERAPY | ||||||
| 10/21/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $26.96 | General |
| Category: Oncology | ||||||
| 10/16/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $15.61 | General |
| Category: UROLOGY | ||||||
| 10/11/2024 | Axonics, Inc. | Axonics (Device) | Food and Beverage | In-kind items and services | $13.65 | General |
| Category: Urology | ||||||
| 09/26/2024 | Verity Pharmaceuticals Inc. | Trelstar (Drug) | Food and Beverage | Cash or cash equivalent | $12.81 | General |
| Category: Prostate cancer | ||||||
| 09/26/2024 | Verity Pharmaceuticals Inc. | Trelstar (Drug) | Food and Beverage | Cash or cash equivalent | $0.70 | General |
| Category: Prostate cancer | ||||||
| 09/23/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,100.00 | General |
| Category: Oncology | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological), WELIREG | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: ONCOLOGY | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A DOUBLE-BLINDED, PLACEBO-CONTROLLED, RANDOMIZED PHASE II STUDY OF ENZALUTAMIDE WITH OR WITHOUT THE PI3 KINASE-MTOR INHIBITOR LY3023414 IN MEN WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER | Eli Lilly and Company | $72.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 36 | 2,322 | 3,185 | $528,795 | $149,975 |
| 2022 | 38 | 1,700 | 3,200 | $385,554 | $116,134 |
| 2021 | 33 | 2,419 | 16,453 | $1.4M | $350,540 |
| 2020 | 33 | 1,803 | 11,434 | $1.1M | $249,125 |
Total Patients
8,244
Total Services
34,272
Medicare Billing
$865,773
Procedure Codes
143
All Medicare Procedures & Services
143 procedure records from CMS Medicare Utilization — Page 1 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 240 | 240 | $62,880 | $24,170 | 38.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 226 | 268 | $45,828 | $22,386 | 48.8% |
| 78815 | Nuclear medicine study from skull base to mid-thigh with ct scan | Office | 2023 | 11 | 12 | $65,400 | $11,951 | 18.3% |
| 74178 | Ct scan of abdomen and pelvis before and after contrast | Office | 2023 | 66 | 67 | $46,498 | $11,142 | 24.0% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 62 | 67 | $36,850 | $10,976 | 29.8% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 152 | 152 | $25,688 | $10,797 | 42.0% |
| 57425 | Surgical repair of vaginal defect using an endoscope | Facility | 2023 | 11 | 11 | $26,158 | $7,710 | 29.5% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 111 | 143 | $32,890 | $6,484 | 19.7% |
| 50590 | Shock wave crushing of kidney stones | Facility | 2023 | 13 | 15 | $24,150 | $6,141 | 25.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 84 | 89 | $10,235 | $5,025 | 49.1% |
| 72197 | Mri scan of pelvis before and after contrast | Office | 2023 | 26 | 26 | $14,419 | $4,391 | 30.5% |
| 74176 | Ct scan of abdomen and pelvis without contrast | Office | 2023 | 58 | 61 | $16,775 | $4,081 | 24.3% |
| 87900 | Infectious agent drug susceptibility analysis | Office | 2023 | 18 | 19 | $6,175 | $2,427 | 39.3% |
| 87799 | Detection test by nucleic acid for organism, quantification | Office | 2023 | 18 | 55 | $7,260 | $2,309 | 31.8% |
| 52332 | Insertion of stent in ureter using an endoscope | Facility | 2023 | 19 | 21 | $32,275 | $2,227 | 6.9% |
| 55700 | Biopsy of prostate gland | Facility | 2023 | 24 | 24 | $9,504 | $1,843 | 19.4% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 95 | 101 | $8,181 | $1,784 | 21.8% |
| 74177 | Ct scan of abdomen and pelvis with contrast | Office | 2023 | 12 | 12 | $6,300 | $1,652 | 26.2% |
| 81003 | Automated urinalysis test | Office | 2023 | 553 | 694 | $6,940 | $1,502 | 21.6% |
| 87798 | Detection test by nucleic acid for organism, amplified probe technique | Office | 2023 | 18 | 38 | $4,104 | $1,307 | 31.8% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 117 | 133 | $1,596 | $1,110 | 69.5% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2023 | 19 | 19 | $2,204 | $877.03 | 39.8% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Facility | 2023 | 19 | 19 | $10,072 | $835.64 | 8.3% |
| 87652 | Detection test by nucleic acid for strep (streptococcus, group a), quantification | Office | 2023 | 18 | 19 | $2,451 | $777.48 | 31.7% |
| 87481 | Detection test for candida species (yeast), amplified probe technique | Office | 2023 | 18 | 19 | $2,052 | $653.41 | 31.8% |
About Dr. Ralph Henderson, M.D
Dr. Ralph Henderson, M.D is a Urology healthcare provider based in Shreveport, Louisiana. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/20/2005. The National Provider Identifier (NPI) number assigned to this provider is 1164427621.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ralph Henderson, M.D has received a total of $285,525 in payments from pharmaceutical and medical device companies, with $24,444 received in 2024. These payments were reported across 641 transactions from 49 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($128,400).
As a Medicare-enrolled provider, Henderson has provided services to 8,244 Medicare beneficiaries, totaling 34,272 services with total Medicare billing of $865,773. Data is available for 4 years (2020–2023), covering 143 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Location Shreveport, LA
- Active Since 06/20/2005
- Last Updated 04/29/2010
- Taxonomy Code 208800000X
- Entity Type Individual
- NPI Number 1164427621
Products in Payments
- Erleada (Drug) $101,467
- ERLEADA (Drug) $47,050
- Nubeqa (Drug) $9,768
- PROVENGE (Drug) $8,477
- DARZALEX (Biological) $8,286
- RUBRACA (Drug) $6,897
- XTANDI (Drug) $6,649
- Xtandi (Drug) $5,899
- Bavencio (Biological) $5,058
- Xofigo (Drug) $4,558
- ELIGARD (Drug) $4,442
- ADSTILADRIN (Drug) $3,756
- IMFINZI (Drug) $3,594
- FOUNDATIONACT (Device) $3,256
- CYSVIEW (Drug) $3,000
- LYNPARZA (Drug) $2,609
- PYLARIFY (Drug) $2,568
- IMFINZI (Biological) $1,395
- JELMYTO (Drug) $1,286
- SpaceOAR (Device) $1,251
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Urology Doctors in Shreveport
Dr. Kevin Hebert, M.d, M.D
Urology — Payments: $53,214
Urology $53,214
Mrs. Ashley Baker, M.d, M.D
Urology — Payments: $22,792
Urology $22,792
Dr. David Price, M.d, M.D
Urology — Payments: $22,270
Urology $22,270
Dr. Nazih Khater, M.d, M.D
Urology — Payments: $21,942
Urology $21,942
Kevin Cline, Md, MD
Urology — Payments: $20,853
Urology $20,853
Jared Moss, Md, MD
Urology — Payments: $17,420
Urology $17,420